ITM Isotope Technologies Munich SE (ITM), a radiopharmaceutical theranostics company, announced the opening its U.S. headquarters in Princeton, New Jersey and appointed Roger Estafanos as U.S. General Manager. Mr.
Estafanos brings a wealth of experience from both the radiopharmaceutical and pharmaceutical industries including being one of the first leaders of the US division of Advanced Accelerator Applications (AAA), a Novartis company. His arrival builds on ITM’s appointment of key hires to its U.S. leadership team in 2022. Establishing the headquarters in
Princeton strengthens ITM’s ongoing expansion of its U.S. business, including the sales and marketing of the company’s therapeutic and diagnostic radioisotopes, while preparing for potential market registration of its targeted radiopharmaceutical pipeline product candidates currently in development.
“With the high-profile addition of Roger to our strong U.S. leadership team and a prime headquarter location secured in Princeton’s pharmaceutical and biotech cluster, we are increasing the strength of our capabilities to serve the healthcare community and our partners around the world with our highly pure n.c.a. lutetium-177. This growth will accelerate us on ITM’s path toward the potential market approval of ITM-11 and we remain committed to developing new radiopharmaceuticals for patients living with hard-to-treat cancers,” commented Steffen Schuster, CEO of ITM.
"ITM is a global leader in providing radionuclide therapies and diagnostics to patients in need through its own products and its central role in contributing to its partners’ radiopharmaceutical treatments. I am thrilled to collaborate with this exceptional, passionate and knowledgeable team driving innovation in nuclear medicine to reach the full potential of this critically important modality,” concluded Roger Estafanos, U.S. General Manager of ITM.
Roger Estafanos joins ITM from Advanced Accelerator Applications (AAA), a Novartis Company, where he most recently held the position of VP, Head of Commercial and Access Realization. During his time at AAA, he played a crucial role in launching the company’s therapeutic and diagnostic radiopharmaceutical portfolio. Before joining Novartis / AAA, Roger garnered 15 years of experience in management consulting, providing strategic advice to pharmaceutical, biotech, medical, and diagnostic companies on commercializing products across various disease areas. His leadership roles span across top life sciences consulting firms, including IBM Global Business Services, IQVIA, and Peppers & Rogers Group. Mr. Estafanos earned his undergraduate degree in Information Systems from Rutgers University and completed his MBA at Rutgers Business School.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!